<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00504101</url>
  </required_header>
  <id_info>
    <org_study_id>20070104</org_study_id>
    <secondary_id>SCCC-2006071</secondary_id>
    <nct_id>NCT00504101</nct_id>
  </id_info>
  <brief_title>Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma</brief_title>
  <official_title>Phase I Clinical Trial of Dose Escalated Bortezomib + ATO (Arsenic Trioxide) + Melphalan as a Conditioning Regimen for Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes&#xD;
      needed for cell growth. Drugs used in chemotherapy, such as arsenic trioxide and melphalan,&#xD;
      work in different ways to stop the growth of cancer cells, either by killing the cells or by&#xD;
      stopping them from dividing. Giving high-dose combination chemotherapy together with&#xD;
      bortezomib may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib when&#xD;
      given together with arsenic trioxide and melphalan in treating patients undergoing an&#xD;
      autologous stem cell transplant for multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Evaluate toxicity of a conditioning treatment regimen comprising bortezomib, arsenic&#xD;
           trioxide, and melphalan.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Evaluate response and overall survival.&#xD;
&#xD;
        -  Determine what correlative laboratory and clinical parameters, if any, are associated&#xD;
           with efficacy (e.g., serum arsenic trioxide intracellular glutathione depletion, gene&#xD;
           profiling of myeloma cells).&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of bortezomib.&#xD;
&#xD;
        -  Conditioning regimen: Bortezomib will be given on days -6, -4, and -2, arsenic trioxide&#xD;
           will be given on days -6, -5, -4, -3, and -2 (total of 5 doses), and melphalan will be&#xD;
           given on day -2.&#xD;
&#xD;
        -  Stem cell infusion: On day 0 a minimum of autologous 2 x 10^6 CD34 cells/kg will be&#xD;
           infused by central catheter.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically for at least 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Temporarily closed to accrual pending availablity of drug.&#xD;
  </why_stopped>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate toxicity of the conditioning treatment regimen.</measure>
    <time_frame>3 ¼ years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate response and overall survival (OS).</measure>
    <time_frame>3 ¼ years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine what correlative laboratory and clinical parameters, if any, are associated with efficacy</measure>
    <time_frame>3 ¼ years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arsenic trioxide</intervention_name>
    <description>Arsenic Trioxide will be given on day -6, -5, -4,-3,-2 (total of 5 doses). The dose of Arsenic trioxide (ATO) is 0.25 mg/m2.</description>
    <other_name>ATO (As2O3)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Bortezomib will be given on day -6, -4, -2 (total 3 doses) beginning at a dose of 0.8 mg/m2 each day of therapy.</description>
    <other_name>Velcade</other_name>
    <other_name>PS-341</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan will be given at 200 mg/m2 on day -2 (1 dose only)</description>
    <other_name>L-PAM</other_name>
    <other_name>L-phenylalanine mustard</other_name>
    <other_name>L-sarcolysin</other_name>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous hematopoietic stem cell transplantation</intervention_name>
    <description>On day 0 a minimal of 2 x 106 CD 34 cells/kg will be infused by central catheter according to institutional standards.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of multiple myeloma (M-protein by serum protein electrophoresis or&#xD;
             urine protein electrophoresis) and either bone marrow biopsy and aspirate&#xD;
             demonstrating a plasma cell count &gt; 10% or biopsy of a bone or soft tissue mass&#xD;
             demonstrating a plasmacytoma&#xD;
&#xD;
               -  Demonstration of an indication for therapy based on symptoms (e.g., boney pain),&#xD;
                  hypercalcemia, anemia, renal insufficiency, symptomatic plasmacytomas, multiple&#xD;
                  boney lytic lesions, etc&#xD;
&#xD;
               -  Stable disease or has achieved a partial remission or complete remission to&#xD;
                  pre-transplant cyto-reductive therapy&#xD;
&#xD;
               -  Primary refractory disease (no response to therapy but stable) is permitted&#xD;
&#xD;
          -  Candidate for high-dose chemotherapy with autologous stem cell transplantation based&#xD;
             on stabilization of disease with preparative chemotherapy (regardless of the specific&#xD;
             agents)&#xD;
&#xD;
          -  A minimum of 2 x 10^6 CD34+ cells/kg must be collected prior to proceeding to&#xD;
             transplant&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Evidence of active plasma cell leukemia&#xD;
&#xD;
          -  Relapsed refractory disease (patients who have achieved at least a partial response&#xD;
             [PR] to previous therapy and are now refractory [have not achieved a PR to subsequent&#xD;
             therapy])&#xD;
&#xD;
          -  Progressive disease on their last therapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Karnofsky performance status 60-100%&#xD;
&#xD;
          -  Creatinine &lt; 3.0 mg/dL&#xD;
&#xD;
          -  AST and ALT &lt;2.5 times upper limit of normal&#xD;
&#xD;
          -  Total bilirubin &lt; 3 mg/dL&#xD;
&#xD;
          -  WBC ≥ 2,000/mm³&#xD;
&#xD;
          -  Platelet count ≥ 50,000/mm³&#xD;
&#xD;
          -  If abnormal hematologic function is attributable to bone marrow infiltration by&#xD;
             multiple myeloma, the principal investigator will decide on a case-by-case basis if&#xD;
             the patient's bone marrow reserve is appropriate for this study&#xD;
&#xD;
          -  Females of childbearing potential must have a negative serum pregnancy test prior to&#xD;
             enrollment on the study and must use an effective barrier method while on the study&#xD;
&#xD;
          -  Ejection fraction &gt; 40% and no history of uncontrolled ischemic heart disease or&#xD;
             congestive heart failure&#xD;
&#xD;
          -  No evidence of cardiac amyloidosis by echocardiogram&#xD;
&#xD;
          -  DLCO and FEV_1 ≥ 50%&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Active peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  Recurrent supraventricular arrhythmia or any type of sustained ventricular arrhythmia&#xD;
             or conduction block (e.g., A-V block grade II or III, left bundle branch block)&#xD;
&#xD;
          -  Known HIV infection&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Underlying medical condition that could be aggravated by the treatment or&#xD;
             life-threatening disease unrelated to myeloma as evaluated by the enrolling physician&#xD;
&#xD;
          -  History of second malignancy within the past 3 years and not in complete remission&#xD;
             from that malignancy, excluding adequately treated basal or squamous cell carcinoma of&#xD;
             the skin, carcinoma in situ of the cervix, or local prostate cancer&#xD;
&#xD;
          -  History of preexisting neurological disorders (grade 2 or higher by the NCI Common&#xD;
             Toxicity Criteria, in particular seizure disorders)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Previous radiation therapy for palliation of cord compression or pathologic fractures&#xD;
             is permitted provided last dose is given 14 days prior to initiation of chemotherapy&#xD;
&#xD;
          -  Subjects with radiographic evidence of lytic bone disease receiving concomitant&#xD;
             bisphosphonate therapy may be enrolled&#xD;
&#xD;
               -  Bisphosphonates should be held at least 1 week prior to the transplant but&#xD;
                  continuing bisphosphonates after day +60 is at the discretion of the treating&#xD;
                  physician&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Previous autologous or allogeneic transplantation&#xD;
&#xD;
          -  Other investigational or experimental drug or therapy while on the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark S. Goodman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Miami Sylvester Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center - Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>July 17, 2007</study_first_submitted>
  <study_first_submitted_qc>July 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2007</study_first_posted>
  <last_update_submitted>December 14, 2016</last_update_submitted>
  <last_update_submitted_qc>December 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Arsenic Trioxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

